Peer review of Pfizer COVID-19 vaccine data confirms 100% effectiveness in adolescents
A new study published in the New England Journal of Medicine is confirming Pfizer’s claims of the high levels of effectiveness among adolescents of its COVID-19 vaccine. The study, which looked at 2,260 adolescents between the ages of 12 and 15, observed 100% efficacy in the group, with a favorable safety and side-effect profile. The authors conclude that the Pfizer vaccine produces a greater immune response for adolescents than it does in young adults.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…